91 results about "Shigella flexneri" patented technology

The present invention relates to protein-protein interactions between Shigella polypeptides and mammalian polypeptides. More specifically, the present invention relates to complexes of polypeptides or polynucleotides encoding the polypeptides, fragments of the polypeptides, antibodies to the complexes, Selected Interacting Domains (SID(R)) which are identified due to the protein-protein interactions, methods for screening drugs for agents which modulate the interaction of proteins and pharmaceutical compositions that are capable of modulating the protein-protein interactions.

The invention relates to a phage strain and application thereof. The preserving number of the phage strain is CCTCC NO: M209029; and the strain has strong cracking function for Shigella flexneri. After the phage strain is purified, amplified and cultured, the phage strain can be used for inhibiting the Shigella flexneri. The phage strain has the following advantages: because the Shigella flexneri with drug resistance can be killed by adopting the specificity of the phage strain to crack the Shigella flexneri, simultaneously the evolution of the Shigella flexneri and the generation of drug-resistant strains can be prevented; because the phage strain has an aqueous phase, flushing liquor or leacheate for sterilizing environments or apparatuses can be easily prepared by the prior method; and because the phage strain can specifically crack the Shigella flexneri and has no toxic and side effects, the phage strain can be used as a food additive to prevent the Shigella flexneri from polluting food, and used as a medicament for treating the diseases caused by the Shigella flexneri.

The invention provides a lactobacillus plantarum AB-3 strain having an activity of resisting phytophthora melonis kalsura, of which the accession number is CGMCC No.9655. The lactobacillus plantarum AB-3 has effective inhibition properties on escherichia coli, salmonella typhimurium and shigella flexneri, has effective inhibition properties on the phytophthora melonis kalsura, fusarium oxysporum, penicillium roqueforti and glomerella cingulata and is excellent in thermostability. A fermentation supernate of the strain shows a significantly increased bacteria inhibition rate after treatment at 100 DEG C and is enhanced in bacteria inhibition activity through enzymolysis by a neutral protease. The fermentation supernate of the strain has a storage resistance property and is excellent in bacteria inhibition activity even after normal storage for 20 days.

A conjugate molecule comprising an oligo- or polysaccharide covalently bound to a carrier and its use as potential vaccine against infection by S. Flexneri.

The invention relates to genetic engineering of Scylla paramamosain, and provides a Scylla paramamosain anti-lipopolysaccharide factor, and a preparation method and application thereof. The preparation method comprises the following steps: building a recombinant expression vector for the Scylla paramamosain anti-lipopolysaccharide factor; introducing the recombinant expression vector into host cells, and carrying out induced expression on the host cells to obtain an expression product; and separating and purifying the expression product to obtain a recombinant protein, namely the Scylla paramamosain anti-lipopolysaccharide factor. The Scylla paramamosain anti-lipopolysaccharide factor has obvious growth inhibition and sterilization effects on Gram-negative bacteria such as Shigella flexneri, Vibrio alginolyiicus, Vibrio parahaemolyticus, Pseudomonas stutzeri and Pseudomonas fluorescens and Gram-positive bacteria such as Corynebacterium glutamicum, and has a potential application value in the preparation of antibacterial medicaments and antimicrobial additives for animal feed.

The invention relates to a primer for detecting the serotype of shigella flexneri, and the method comprises the following sequences: SEQ ID Nos. 1 and 2 (sequence identity numbers 1 and 2), SEQ ID Nos. 3 and 4, SEQ ID Nos. 5 and 6, SEQ ID Nos. 7 and 8, SEQ ID Nos. 9 and 10, SEQ ID Nos. 11 and 12, SEQ ID Nos. 13 and 14, and SEQ ID Nos. 15 and 16. The primer has specificity and consistent annealingtemperature. The invention further relates to a method for performing multiplex amplification by utilizing the primer. The invention further relates to an application of the primer in detecting the serotype of the shigella flexneri in the preparation of detection agents. The invention further relates to a kit containing the primer for detecting the serotype of the shigella flexneri.

The invention discloses a multiple-PCR detection method for pathogenetic bacteria in soil, which is characterized in that: multiple PCR is adopted to simultaneously amplify specific genes of enteropathogenic E. Coli, salmonella, Staphylococcus aureus, pseudomonas aeruginosa and Shigella flexneri for one time, namely phoA, ttrBCA, vicK, ecfX, ipaH and virA, and then PCR amplification products are detected by agarose gel electrophoresis. The multiple-PCR detection method overcomes defects of complicated operation, time and labor consumption and the like of the conventional pathogenetic bacteria detection technology, fully applies the multiple-PCR detection technology in detecting the pathogenetic bacteria in the soil, increases the types of the pathogenetic bacteria and number of pairs of primers as possible, and improves the specificity and sensitivity of the detection.

The invention discloses a Shigella flora / serotype multiplex-PCR (polymerase chain reaction) detection primer set and kit. The detection primer set is composed of primer pairs for detecting Shigella sonnei, type-1-5 Shigella flexneri, type-I Shigella dysenteriae, type-6 Shigella flexneri, and Shigella. According to the invention, a multiplex-PCR detection method based on a common PCR platform is built; according to the method, multiplex-PCR reaction is carried out on total DNA of bacteria extracted from a sample to be detected in a same reaction system by using the primer pairs obtained through analysis and design, and through electrophoretic analysis on a reaction product, whether the sample is Shigella can be determined and Shigella flora / serotype can be judged.

The invention provides a bacteriocin, and a preparation method and an application thereof. The bacteriocin belongs to broad spectrum bacteriocin, and an antibacterial spectrum comprises Gram-negative bacteria and Gram-positive bacteria, such as Pseudomonas putida, Bacillus subtilis, Listeria monocytogenes, Shigella flexneri, Staphylococcus citreus, Escherichia coli and salmonella.

The invention provides an environment biological disinfectant with phages as main components and application thereof. The biological disinfectant is composed of Escherichia coli phage CCTCC (China Center for Type Culture Collection) M209208, Bacterium enteritidis phage CCTCC M2010226, Salmonella pullorum phage CCTCC M2011042, Shigella flexneri phage CCTCC M209029, cinnamon extract, Chinese pulsatilla extract and auxiliary agents, wherein the purified phages are prepared into liquid with the concentration of more than or equal to 10<4> pfu (plaque forming unit) / mL, and are used for sterilizing and cleansing environment places and devices. The biological disinfectant has the characteristics of strong sterilization capability, rapid sterilization, no toxicity or harm, no irritation, no corrosion, no colorizing performance and the like, is especially suitable for disinfection and cleansing of breeding farms, slaughter houses, livestock product processing factories, food warehouses and other environments and devices, and has better popularization and use values.

The invention discloses fluorescent quantitative polymerase chain reaction (PCR) primers and probes for detecting pathogenic bacteria of multiple aquatic products simultaneously and a detection method, and belongs to the field of molecular detection. Five groups of the fluorescent quantitative PCR primers and the probes are provided and can be used for detecting salmonella, listeria monocytogenes, vibrio parahaemolyticus, shigella flexneri and vibrio cholerae non-O1 respectively, wherein except the primers and the probes for listeria monocytogenes genes and the primers and the probes for vibrio parahaemolyticus genes cannot be used simultaneously, the pathogenic bacteria which can be detected by the corresponding primers and probes can be detected simultaneously by combining any other two groups or more than two groups of the primers and probes. The invention also discloses multiple fluorescent quantitative PCR amplification systems which are constructed by using the primers and the probes, so the primers and the probes can detect whether samples to be detected contain the corresponding pathogenic bacteria or not quickly and accurately, are convenient to operate and high in specificity, can be made into kits and the like and are applicable to the detection of the pathogenic bacteria of the subsidiary agricultural products, and a false positive result is avoided.

The invention provides a bacteriophage composition, a bacteriostatic agent and application thereof, and belongs to the technical field of bioengineering. The bacteriophage composition comprises a clostridium perfringens bacteriophage (CCTCC NO: M2020047), a salmonella bacteriophage (CCTCC NO: M2020710), an escherichia coli bacteriophage (CCTCC NO: M2020711) and a shigella flexneri bacteriophage (CCTCC NO: M209029). The bacteriophage composition has a strong lysis effect on clostridium perfringens, salmonella, escherichia coli and shigella flexneri, and can be used for inhibiting and / or eliminating clostridium perfringens, salmonella, escherichia coli and shigella flexneri; by inhibiting the overgrowth of clostridium perfringens, salmonella, escherichia coli and shigella flexneri, the occurrence of intestinal diseases of animals is effectively prevented and controlled; a safe bacteriophage antibacterial product source without toxic and side effects is provided for preventing and controlling animal intestinal diseases caused by clostridium perfringens, salmonella, escherichia coli and shigella flexneri.

The present invention provides a salmonella mutant strain capable of efficiently stimulating hosts to produce immune responses against shigella flexneri 2a serotype O antigen polysaccharides, and a construction method and an application of the salmonella mutant strain, and belongs to the technical field of bioengineering. The provided salmonella mutant strain has the following gene deletion mutations delta-fliC, delta-fljB, delta-ompA, delta-ompC and delta-ompD, a gene rfbP that is conducive to expression of heterologous O antigen polysaccharides is knocked out, and at the same time, expression plasmids capable of completely expressing the shigella flexneri O antigen polysaccharides are transferred. A preservation number of the salmonella mutant strain is CCTCC NO:M 2020142 and the salmonella mutant strain is preserved in the China Center for Type Culture Collection. By modifying an outer membrane structure of the salmonella, the salmonella mutant strain is more efficient to be used asa polysaccharide presentation carrier. At the same time, the O antigen polysaccharides of the shigella flexneri are expressed in the outer membrane of the salmonella, outer membrane vesicles are purified, the salmonella mutant strain can efficiently stimulate the hosts to produce the immune responses and secrete the outer membrane vesicles, thereby presenting heterologous polysaccharide antigen as a vaccine, and the salmonella mutant strain can be effectively used for prevention and treatment of shigella infection.

The invention relates to a helicobacter pylori viable bacteria carrier vaccine and special recombination bacteria thereof. The special recombination bacteria is recombination Shigella flexneri (Sh.flexneri) which is obtained by introducing coding gene of fusion protein containing helicobacter pylori urease B subunit and helicobacter pylori heat shock protein A subunit into the Shigella flexneri (Sh.flexneri). The active ingredient of the helicobacter pylori viable bacteria carrier vaccine is the recombined Shigella flexneri (Sh.flexneri). Animal test proves that the helicobacter pylori vaccine bacterial strain has favorable immunogenicity and protective immunity.

The invention relates to a Shigella flexneri serotype detection primer, and multiplex amplification using it. The primer comprises sequences represented by SEQ ID Nos.2 and 3, SEQ ID Nos.4 and 5, SEQ ID Nos.6 and 7, SEQ ID Nos.8 and 9, SEQ ID Nos.10 and 11, SEQ ID Nos.12 and 13, SEQ ID Nos.14 and 15, SEQ ID Nos.16 and 17, SEQ ID Nos.18 and 19. The primer is specific and has an annealing temperature consistency. The invention also relates to a method for realizing the multiplex amplification by using the primer, and further relates to an application of the Shigella flexneri serotype detection primer in the preparation of a detection agent, and a Shigella flexneri serotype detection kit including the primer.

The invention discloses a nontoxic shigella flexneri with lipopolysaccharide synthesis deficiency and a construction method thereof. The invention provides a recombinant bacterium A, which is a recombinant bacterium obtained by removing large virulence plasmid in shigella flexneri 2a and O-antigen ligase coding gene in genome of the shigella flexneri 2a. Experiments show that according to the method of the invention, large virulence plasmid in shigella flexneri 2a 301 is firstly removed based on a plasmid exclusion principle, and a large virulence plasmid traceless deletion mutant 301 delta pCP is constructed, which is the nontoxic shigella flexneri; a target gene is substituted by a resistance gene by using homologous recombination technology based on the action of lambda bacteriophage Red recombinase; then the resistance gene is removed from a host bacterium under the action of transposase, and thus a waaI deletion strain of the nontoxic shigella flexneri is obtained.

The invention discloses a novel application of an embelin or embelin compound in bacterium inhibition. According to the novel application, the embelin or embelin compound has an effect of inhibiting enzyme activity of beta-lactamase, especially a prominent effect of inhibiting the wide anti-biological hydrolytic activity of New Delhi metallo-beta-lactamase-1, can be used for remarkably improving the sensitivity of drug-resistance bacteria on antibiotics, remarkably reducing the minimal inhibitory concentration of multiple antibiotics on superbug, reversing the drug resistance of drug-resistance bacteria and reducing clinical hazard of serious drug-resistance bacteria, and has certain bacteriostatic activity. A high-concentration embelin or embelin compound has remarkable bacteriostatic activity on staphylococcus aureus, pseudomonas aeruginosa, salmonella typhimurium, shigella sonnei, shigella flexneri, klebsiella pneumoniae, escherichia coli and other pathogenic bacteria, and even can be used for completely inhibiting bacterium growth.

The invention discloses application of a medicine composition for treating cold to preparing antibacterial medicine. The medicine composition is prepared from, by weight, 1-9 parts of ephedra, 1-9 parts of mint, 1-9 parts of periostracum cicada, 1-20 parts of honeysuckle, 2-20 parts of radix scutellariae, 2-18 parts of apricot kernels, 1-9 parts of fritillary bulb, 1-9 parts of platycodon grandiflorum and 1-9 parts of liquorice. Conventional auxiliary materials are added into the raw materials, and the mixture is prepared into clinically accepted tablets, granules, pills, capsules, drop pills, soft capsules, sustained-releasing drugs, oral liquid preparations or freeze-dried powder injections according to the conventional technology. New application is developed, and new medicine is provided for treatment of bacteria infected by staphylococcus aureus, escherichia coli, pseudomonas aeruginosa, shigella flexneri and proteus.

The invention provides a Chinese mosla-essential oil antibacterial soap and a preparation method thereof. The antibacterial soap is prepared from the following raw materials in parts by weight: 130-140 parts of coconut oil, 260-270 parts of beef tallow, 180-185 parts of an ethanol water solution, 55-65 parts of water, 190-200 parts of a NaOH water solution and 4-6 parts of Chinese mosla essentialoil. According to the Chinese mosla-essential oil antibacterial soap disclosed by the invention, Chinese mosla is processed and produced at a producing area in an integrated mode, essential oil in theChinese mosla is extracted by taking the Chinese mosla as a raw material and serves as an antibacterial active ingredient, and natural components such as the coconut oil and the beef tallow are matched, so that irritation and harm of chemical antibacterial agents to human bodies are avoided. The antibacterial soap has natural aroma, and addition of chemical aromatics are not needed. Tests prove that the Chinese mosla-essential oil antibacterial soap disclosed by the invention has obvious antibacterial effects on Shigella flexneri, salmonella typhimurium, staphylococcus aureus, escherichia coli and the like, and has a good antibacterial effect.

The invention discloses a Shigella multivalent conjugate vaccine which includes five serotypes, i.e., Shigella dysenteriae I type, Shigella flexneri 2a type, Shigella flexneri 3a type, Shigella flexneri 6 type and Shigella sonnei; the Shigella multivalent conjugate vaccine is prepared by the steps of preparing conjugate stock solutions from specific polysaccharides of the bacteria and carrier protein, and mixing five conjugate stock solutions in a proper proportion. The prepared conjugate vaccine disclosed by the invention is applicable to immunoprophylaxis of Shigella infection.

The invention discloses a common primer-mediated PCR kit for detecting 11 food-borne pathogenic bacteria and an application of the common primer-mediated PCR kit. A common primer-mediated multiplex PCR technology is utilized; specific genes of 11 common food-borne pathogenic bacteria (salmonella, listeria monocytogenes, shigella flexneri, enterohemorrhagic escherichia coli O157, vibrio parahaemolyticus, staphylococcus aureus, vibrio cholerae, clostridium botulinum A, bacillus cereus, clostridium perfringens and yersinia enterocolitica) are used as detection markers; an efficient, high-specificity and high-flux multiplex PCR detection system is established, and a nucleic acid detection kit suitable for detecting the common food-borne pathogenic bacteria is researched and developed. The sensitivity of the common primers reaches 10<3> copies / mu L, a UP-M-PCR system for simultaneously detecting the 11 food-borne pathogenic bacteria is constructed, single-template and two-template experiments prove that the UP-M-PCR system has good specificity, and the sensitivity of a bacterial genome DNA detection system is as high as 0.01 ng / mu L.

The ospF gene of Shigella flexneri encodes a phosphatase, which is a member of a new class of phosphatases. The OspF phosphatase inhibits the activity of several proteins either by direct protein modification or transcription downregulation. These proteins include MAP kinase, IL-8, CCL20, IL-12, AP1, CREB, RPA p32, and BCL2 related proteins. Methods for treating diseases using OspF phosphatase, methods for identifying agents that modulate OspF phosphatase's activity, methods for identifying agents that mimic OspF phosphatase's activity, and immunogenic compositions comprising OspF phosphatase are provided. A strain of Shigella flexneri containing an inactivated ospF gene is also provided.

Virulence-associated antigens involved in adhesin have been identified in several organisms: Haemophilus influenzae biogroup aegyptius; Escherichia coli K1; EHEC E.coli; Actinobacillus actinomycetencomitans; Haemophilus somnus; Haemophilus ducreyi; EPEC E.coli; EA EC E.coli; uropathogenic E.coli; Shigella flexneri; Brucella melitensis; Brucella suis; Ralstonia solanacearum; Sinorhizobium meliloti; Bradorhizobium japonicum; and Burkholderia fungorum. Although the degree of sequence identity between the adhesins is low, they share a common arrangement of domains from N-terminus to C-terminus, namely: a leader peptide; a globular head; a coiled-coil region; and a transmembrane anchor region.

The present invention provides protected tetrasaccharides, their process of preparation and their use in the synthesis of oligosaccharides, in particular fragments of O-antigens from Shigella flexneri, for example of serotype la, lb, 2a, 2b, 3a, X, 4a, 4b, 5a, 5b, 7a or 7b.

The present inventions relates to primers for identifying Shigella flexneri serotypes comprising the sequences of SEQ ID Nos. 1 and 2, SEQ ID Nos. 3 and 4, SEQ ID Nos. 5 and 6, SEQ ID Nos. 7 and 8, SEQ ID Nos. 9 and 10, SEQ ID Nos. 11 and 12, SEQ ID Nos. 13 and 14, SEQ ID Nos. 15 and 16. These primers are specific and have a common annealing temperature. The present invention further relates to a multiplex amplification-based identification method using the primers. The present invention further relates to the use of the primers for identifying Shigella flexneri serotypes for the preparation of identification agents. The present invention further relates to a kit for identifying Shigella flexneri comprising the above primers.

The invention belongs to the technical field of food preservation and particularly relates to a natural mixed bacteriostatic agent and a preparation method thereof. The natural mixed bacteriostatic agent comprises chlorogenic acid, dihydromyricetin and procyanidine. The natural mixed bacteriostatic agent is prepared by the steps of mixing chlorogenic acid, dihydromyricetin and procyanidine in a certain proportion, adding a certain amount of water solution, adequately stirring to dissolve, and regulate the pH value of the solution. The natural mixed bacteriostatic agent has relatively good inhibition effect to 11 different bacteria including staphylococcus aureus, escherichia coli, Shigella flexneri, proteus mirabilis, Pseudomonas aeruginosa and the like and is expected to be used as an environment-friendly, safe and efficient preservative to be applied to food processing.

The invention discloses an antibacterial peptide Scybaumancin105-127 and application thereof, the antibacterial peptide is found in Scylla paramamosain for the first time, the molecular formula of the antibacterial peptide is C106H188N36O28S3, and the amino acid sequence of the antibacterial peptide is as shown in SEQ ID NO.1. The antibacterial peptide Scybaumancin105-127 disclosed by the invention has good antibacterial activity on acinetobacter baumannii, shigella flexneri, escherichia coli, pseudomonas aeruginosa, cryptococcus neoformans, listeria monocytogenes, enterococcus faecium and propionibacterium acnes, and has no cytotoxicity on normal cells. The antibacterial peptide Scybaumancin105-127 has high antibacterial activity, safety and non-toxic, also has relatively strong antibacterial activity on clinical drug-resistant bacteria, and has a wide application prospect.

The invention provides an application of amomum tsao-ko oil in preparation of drugs for treating bacterial infectious diseases. The bacteria may be coagulase negative staphylococci, kurthia gibsonii, megacoccus, corynebacterium, enterococcus faecalis, bacillus, escherichia coli, monad, acinetobacter lwoffii, flavobacterium indologenes, enterobacter cloacae, flexneri or common mycetozoan. The drugs mentioned in the invention have antimicrobial activity to gram-positive bacterium and gram-negative bacterium, also have high bacteriostatic action to persister therein and simultaneously have good antibacterial action in body, so the drugs can effectively treat infectious diseases caused by various strains in gram-positive bacterium and gram-negative bacterium, therefore the invention provides a new drug use option for clinic.